Assessment of second-line antiretroviral regimens for HIV therapy in Africa by Paton, NI et al.
original article
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 371;3 nejm.org july 17, 2014234
Assessment of Second-Line Antiretroviral 
Regimens for HIV Therapy in Africa
Nicholas I. Paton, M.D., Cissy Kityo, M.Sc., Anne Hoppe, Ph.D.,  
Andrew Reid, M.R.C.P., Andrew Kambugu, M.Med., Abbas Lugemwa, M.D.,  
Joep J. van Oosterhout, Ph.D., Mary Kiconco, M.P.H., Abraham Siika, M.Med.,  
Raymond Mwebaze, M.Med., Mary Abwola, M.Med., George Abongomera, M.Sc.,  
Aggrey Mweemba, M.Med., Hillary Alima, M.P.H., Dickens Atwongyeire, M.B., Ch.B.,  
Rose Nyirenda, M.Sc., Justine Boles, M.Sc., Jennifer Thompson, M.Sc.,  
Dinah Tumukunde, M.P.H., Ennie Chidziva, Dipl.G.N., Ivan Mambule, M.B., Ch.B., 
Jose R. Arribas, M.D., Philippa J. Easterbrook, M.D., James Hakim, F.R.C.P.,  
A. Sarah Walker, Ph.D., and Peter Mugyenyi, F.R.C.P., for the EARNEST Trial Team*
From the Medical Research Council Clini-
cal Trials Unit at University College London, 
London (N.I.P., A.H., J.B., J.T., A.S.W.); 
Yong Loo Lin School of Medicine, National 
University of Singapore, Singapore (N.I.P.); 
Joint Clinical Research Centre (JCRC) (C.K., 
D.T., P.M.), Infectious Diseases Institute 
(A.K., I.M., P.J.E.), and St. Francis of Nsam-
bya Hospital (R.M.), Kampala, JCRC, 
Mbarara (A.L.), JCRC, Fort Portal (M.K.), 
JCRC, Mbale (M.A.), JCRC, Gulu (G.A.), 
JCRC, Kabale (H.A.), and JCRC, Kakira 
(D.A.) — all in Uganda; University of 
Zimbabwe Clinical Research Centre, Ha-
rare (A.R., E.C., J.H.); Malawi–Liverpool–
Wellcome Trust Clinical Research Pro-
gramme, University of Malawi College of 
Medicine, Blantyre ( J.J.O.), Dignitas In-
ternational, Zomba (J.J.O.), and Mzuzu 
Central Hospital, Mzuzu (R.N.) — all in 
Malawi; Moi University School of Medicine, 
Eldoret, Kenya (A.S.); University Teaching 
Hospital, Lusaka, Zambia (A.M.); and Hos-
pital La Paz, Madrid (J.R.A.). Address re-
print requests to Dr. Paton at the Depart-
ment of Medicine, Yong Loo Lin School 
of Medicine, NUHS Tower Block Level 10, 
1E Kent Ridge Rd., Singapore 119228, Singa-
pore, or at nick_paton@nuhs.edu.sg.
Drs. Walker and Mugyenyi contributed 
equally to this article.
* A complete list of members of the Europe–
Africa Research Network for Evaluation 
of Second-Line Therapy (EARNEST) Trial 
Team is provided in the Supplementary 
Appendix, available at NEJM.org.
N Engl J Med 2014;371:234-47.
DOI: 10.1056/NEJMoa1311274
Copyright © 2014 Massachusetts Medical Society.
A BS TR AC T
Background
The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) 
are uncertain when these agents are used with a protease inhibitor in second-line 
therapy for human immunodeficiency virus (HIV) infection in resource-limited set-
tings. Removing the NRTIs or replacing them with raltegravir may provide a benefit. 
Methods
In this open-label trial in sub-Saharan Africa, we randomly assigned 1277 adults and 
adolescents with HIV infection and first-line treatment failure to receive a ritonavir-
boosted protease inhibitor (lopinavir–ritonavir) plus clinician-selected NRTIs (NRTI 
group, 426 patients), a protease inhibitor plus raltegravir in a superiority comparison 
(raltegravir group, 433 patients), or protease-inhibitor monotherapy after 12 weeks of 
induction therapy with raltegravir in a noninferiority comparison (monotherapy group, 
418 patients). The primary composite end point, good HIV disease control, was 
defined as survival with no new World Health Organization stage 4 events, a CD4+ 
count of more than 250 cells per cubic millimeter, and a viral load of less than 
10,000 copies per milliliter or 10,000 copies or more with no protease resistance 
mutations at week 96 and was analyzed with the use of imputation of data (≤4%).
Results
Good HIV disease control was achieved in 60% of the patients (mean, 255 patients) in 
the NRTI group, 64% of the patients (mean, 277) in the raltegravir group (P = 0.21 for 
the comparison with the NRTI group; superiority of raltegravir not shown), and 55% 
of the patients (mean, 232) in the monotherapy group (noninferiority of monotherapy 
not shown, based on a 10-percentage-point margin). There was no significant differ-
ence in rates of grade 3 or 4 adverse events among the three groups (P = 0.82). The viral 
load was less than 400 copies per milliliter in 86% of patients in the NRTI group, 86% 
in the raltegravir group (P = 0.97), and 61% in the monotherapy group (P<0.001).
Conclusions
When given with a protease inhibitor in second-line therapy, NRTIs retained sub-
stantial virologic activity without evidence of increased toxicity, and there was no 
advantage to replacing them with raltegravir. Virologic control was inferior with 
protease-inhibitor monotherapy. (Funded by European and Developing Countries 
Clinical Trials Partnership and others; EARNEST Current Controlled Trials number, 
ISRCTN 37737787, and ClinicalTrials.gov number, NCT00988039.)
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T he public health approach of the World Health Organization (WHO),1 to-gether with large-scale donor funding, 
has enabled millions of adults and children in 
sub-Saharan Africa who are infected with the 
human immunodeficiency virus (HIV) to have 
access to lifesaving antiretroviral therapy.2 The 
key principle is the use of simplified, standardized 
approaches that are feasible on a large scale in 
resource-limited settings,1,3 including a first-line 
regimen of two nucleoside reverse-transcriptase 
inhibitors (NRTIs) plus one non-NRTI (NNRTI). 
In most settings, treatment is monitored clini-
cally and with the use of CD4+ counts, with typ-
ically late detection of treatment failure, accom-
panied by substantial drug resistance.3,4 Evidence 
supporting the WHO-recommended standard-
ized second-line regimen (a boosted protease in-
hibitor and two NRTIs) is of moderate quality,3,5 
with particular uncertainty around the net contri-
bution of NRTIs. The efficacy of NRTIs is likely 
to be compromised by cross-resistance from mul-
tiple mutations arising during first-line therapy, 
and the drugs carry well-recognized risks of toxic 
effects.
We hypothesized that combining a boosted 
protease inhibitor with raltegravir, a heat-stable 
integrase inhibitor, to create a second-line regi-
men with two completely new drug classes that 
would not be compromised by resistance selected 
from first-line therapy would sufficiently increase 
efficacy and decrease toxicity to justify the in-
creased cost of the regimen. Furthermore, we 
hypothesized that removing NRTIs entirely (using 
a protease inhibitor alone) would be noninferior 
to the standard regimen (as has been shown in 
some first-line studies),6-8 with the advantage of 
reduced toxicity, regimen complexity, and cost.
In the Europe–Africa Research Network for 
Evaluation of Second-Line Therapy (EARNEST) 
trial, we evaluated these three options for second-
line antiretroviral therapy in an approach that is 
currently generalizable to sub-Saharan Africa, 
consisting of clinician-selected NRTIs and clini-
cal and CD4+ monitoring without resistance 
testing or regular monitoring of viral load.
Me thods
Study Patients
From April 12, 2010, to April 29, 2011, we recruited 
patients at 14 centers in five sub-Saharan African 
countries. Eligible patients were HIV-infected adults 
or adolescents (>12 years of age) who had re-
ceived first-line antiretroviral therapy consisting 
of two NRTIs and one NNRTI continuously for 
more than 12 months, had not previously received 
a protease inhibitor, had missed no more than 
3 days of treatment during the preceding month, 
and had virologic, immunologic, or clinical treat-
ment failure (defined according to WHO 2010 
criteria9 and confirmed on the basis of a viral 
load of >400 copies per milliliter at screening). 
Details are provided in the Methods section in 
the Supplementary Appendix and in the study 
protocol, both of which are available with the 
full text of this article at NEJM.org.
Exclusion criteria were current pregnancy 
or breast-feeding, a life expectancy of less than 
1 month, contraindications to any of the study 
drugs or a requirement for concomitant medica-
tions known to interact with any of the study 
drugs, or known positive results on testing for 
hepatitis B surface antigen (testing not required 
at screening).
The protocol was approved by ethics commit-
tees in all participating countries and by the 
research ethics committee at University College 
London. All patients or their caregivers, in the 
case of patients less than 18 years of age, pro-
vided written informed consent.
Study Treatment
Patients were randomly assigned in a 1:1:1 ratio 
to receive a ritonavir-boosted protease inhibitor, 
lopinavir–ritonavir (at a dose of 400 mg of lo pin-
avir and 100 mg of ritonavir twice daily), in com-
bination with two or three new or recycled NRTIs 
chosen without genotyping by the treating clini-
cian (NRTI group); a protease inhibitor in com-
bination with ralteg ravir (at a dose of 400 mg 
twice daily) (raltegravir group); or a protease in-
hibitor alone after ralteg ravir induction for the 
first 12 weeks (monotherapy group). The hypoth-
eses were that the raltegravir-containing combi-
nation would be superior to the NRTI-containing 
combination and that protease-inhibitor mono-
therapy would be noninferior to the NRTI-con-
taining combination.
Randomization was stratified according to 
study center and CD4+ count (<200 cells per cu-
bic millimeter or ≥200 cells per cubic millimeter). 
The computer-generated, sequentially numbered 
randomization list with variable block sizes was 
prepared by the trial statistician and incorporated 
within the Web-hosted secure database. At each 
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center, randomization was performed by the 
trial manager, who could access the next num-
ber but not the whole list.
Clinic visits were scheduled every 4 weeks until 
week 24, then every 6 weeks until week 48, and 
then every 8 weeks until week 96. At each visit, 
patients were seen by nurses or counselors, with 
additional assessment by a clinician every other 
visit; the study drugs were dispensed at each 
visit. Assessments included symptom review, phys-
ical examination, and adherence assessment with 
the use of standardized questions about missed 
doses, with further counseling as indicated. A 
complete blood count was performed and se-
rum alanine aminotransferase and creatinine 
levels were measured at weeks 12, 48, and 96, 
and a CD4+ count was performed every 12 weeks 
until week 48 and then every 16 weeks, with all 
laboratory testing performed locally and results 
returned to the treating clinician. The Cockcroft–
Gault equation was used to calculate the esti-
mated glomerular filtration rate. Additional test-
ing could be performed at the discretion of the 
treating clinician.
Although there was no routine local monitor-
ing of viral load, in cases in which there was 
clinical or immunologic failure (as defined in 
the Methods section in the Supplementary Ap-
pendix) and an alternative regimen was available 
locally, clinicians could perform local open viral-
load testing after approval from an expert review 
committee and could change the treatment if 
appropriate. Substitutions in the antiretroviral 
regimen within drug classes were allowed in 
cases of toxicity. Women in the monotherapy 
group who became pregnant added NRTIs dur-
ing the period in which they were either preg-
nant or breast-feeding. Tuberculosis was treated 
with the use of rifabutin, with no changes in the 
study-drug regimens.
Laboratory Analyses
Viral load was measured centrally at the Joint 
Clinical Research Centre (JCRC) in Kampala, 
Uganda, on samples that were stored at week 48 
and week 96. Laboratory staff members who 
were unaware of study-group assignments per-
formed the analyses using the Abbott RealTime 
HIV-1 assay. Laboratory staff members at Janssen 
Diagnostics in Beerse, Belgium, performed geno-
typic resistance testing by sequencing reverse 
transcriptase, protease, and integrase genes, ac-
cording to study group, in a blinded fashion on 
all postrandomization samples with a viral load 
of more than 1000 copies per milliliter. Genotyp-
ing (reverse transcriptase) of baseline samples 
from patients in the NRTI group was performed 
at the JCRC in Kampala. Drug-susceptibility predic-
tions were made with the use of the Stanford algo-
rithm.10 Results of viral-load measurement and ge-
notyping were not returned to the treating clini-
cians but were reviewed by an independent data 
and safety monitoring committee.
Event Adjudication
The expert review committee, made up of four 
independent physicians with experience in treat-
ing patients with HIV infection, adjudicated re-
ported adverse events against the following stan-
dard prespecified diagnostic criteria: for stage 3 
and 4 events, WHO criteria11; for serious HIV-
associated events not diagnostic of the acquired 
immunodeficiency syndrome (AIDS), criteria 
based on those of the International Network 
for Strategic Initiatives in Global HIV Trials 
(INSIGHT)12; and for all adverse events, the cri-
teria of the Division of AIDS of the National 
Institutes of Health.13 Committee members also 
assessed the relationship between such events 
and the study drugs.
Study End Points
The primary composite end point, good HIV dis-
ease control, was defined as no new WHO stage 4 
events (other than esophageal candidiasis or mu-
cosal herpes simplex virus infection) or death, a 
CD4+ count of more than 250 cells per cubic milli-
meter, and a viral load of less than 10,000 copies 
per milliliter (or ≥10,000 copies per milliliter 
without major or minor protease-inhibitor resis-
tance mutations) at week 96. This end point was 
designed to be pragmatic and to reflect realistic 
outcomes for a public health approach and over-
all patient well-being. (Further rationale for the 
primary end point and a list of secondary end 
points are provided in the Methods section in the 
Supplementary Appendix.)
The protocol specified an analysis of the pri-
mary end point at 96 weeks, but patients were to 
be followed for 144 weeks. The data and safety 
monitoring committee reviewed interim data ap-
proximately annually (at five meetings) with the 
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use of the Haybittle–Peto method (P<0.001).14 At 
their last meeting (on April 15, 2013) after the 
last week 96 visit, committee members recom-
mended that the monotherapy group be stopped 
on the basis of the substantially inferior level of 
viral-load suppression at week 96.
Study Oversight
The pharmaceutical industry partners donated 
medications, test kits, in-kind services, and fund-
ing but had no role in the study design, data col-
lection (other than genotyping), data analysis, 
writing of the manuscript, or the decision to sub-
mit the manuscript for publication. All authors 
vouch for the completeness of the data and anal-
yses presented and the fidelity of this report to 
the protocol.
Statistical Analysis
We estimated that the enrollment of 400 patients 
in each of the three study groups would provide 
a power of 80% to show the noninferiority of 
protease-inhibitor monotherapy, which was de-
fined as an absolute reduction in response of no 
more than 10 percentage points, as compared 
with the NRTI group. This estimation was based 
on the assumption that 75% of the patients in the 
NRTI group would have good HIV disease con-
trol at week 96 (for details, see the Methods sec-
tion in the Supplementary Appendix), with a one-
sided alpha level of 0.025 (because there were 
two randomized comparisons) and assuming 
that 10% of patients would be lost to follow-up. 
The noninferiority margin of 10 percentage points 
was based on Food and Drug Administration 
guidance.15,16 We also estimated that the enroll-
ment of 400 patients in each study group would 
provide a power of 87% to show the superiority 
of the raltegravir regimen if the response was 
10 percentage points higher than that in the 
NRTI group, with a two-sided alpha level of 
0.025 and assuming that 10% of patients would 
be lost to follow-up.
All comparisons were performed in the inten-
tion-to-treat population regardless of changes in 
antiretroviral therapy after randomization. All the 
results presented here are based on two-sided 
statistical tests without adjustment for multiple 
testing. The 95% confidence intervals that are 
presented correspond to a two-sided test for supe-
riority; for comparisons assessing noninferiority, 
the focus is on the lower confidence interval. 
Good HIV disease control at week 96 was com-
pared among the study groups with the use of 
absolute risk differences and logistic regression, 
with multiple imputation for missing CD4+ 
counts, viral loads, and genotypes (which ac-
counted for ≤4% of observations) (Fig. 1). (For de-
tails, see the Methods section in the Supplemen-
tary Appendix.)17,18
Complete case analysis was used for all sec-
ondary end points, with the exclusion of deaths, 
loss to follow-up, and missed visits. Binary end 
points were compared with the use of the risk 
difference and chi-square tests; continuous vari-
ables were compared with the use of the mean 
change from baseline and t-tests or analysis of 
variance. Generalized estimating equations (bi-
nomial or normal distribution, respectively, both 
with independent correlation structure) were used 
as tests of difference between study groups dur-
ing all visit weeks. We used Cox proportional-
hazards regression to analyze time-to-event end 
points. (See the Methods section in the Supple-
mentary Appendix for details with respect to the 
statistical analyses.)
R esult s
Study Patients
Of the 1277 patients who underwent random-
ization, 5 did not meet all entry criteria but 
were included in the analyses, since they all had 
failure of first-line treatment (Table S1 in the 
Supplementary Appendix). Failure of first-line 
treatment was well established, with 42% of pa-
tients having a viral load of more than 100,000 cop-
ies per milliliter, 62% with a CD4+ count of less 
than 100 cells per cubic millimeter, and exten-
sive NRTI resistance, including 57% with interme-
diate- or high-level resistance to tenofovir (Table 1, 
and Table S2 in the Supplementary Appendix). 
The NRTIs that were most frequently selected in 
the NRTI group were tenofovir plus either lamivu-
dine or emtricitabine (in 70% of patients), with 
additional zidovudine in another 9% of patients 
(in accordance with national guidelines in Ma-
lawi) (Table S3 in the Supplementary Appendix).
A total of 6% of the study patients died before 
week 96, 0.7% withdrew from the study, and 
0.7% were lost to follow-up, with similar rates in 
the three study groups (Fig. 1). Among survivors 
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at week 96, the proportions of patients who were 
still taking the appropriate classes of drugs for 
their assigned group were 99% in the NRTI 
group, 97% in the raltegravir group, and 98% in 
the monotherapy group (P = 0.23 for the compari-
son among the three groups); overall, the propor-
tions of person-time receiving drugs consistent 
with the assigned strategy were 99%, 97%, and 
97% in the three groups, respectively, with the 
allowance of within-class substitutions and 
NRTIs added to the regimen in the monothera-
py group in case of pregnancy. Self-reported 
adherence to study medication was high. The 
proportions of visits at which patients reported 
no missed medication doses in the previous 
month were 87% in the NRTI group, 89% in 
the raltegravir group, and 88% in the mono-
therapy group (P = 0.26 for the comparison 
among the three groups); the respective pro-
portions of visits with no missed doses on 
weekends were 96%, 97%, and 96% (P = 0.23), 
and the proportions with no missed doses for 
4 or more consecutive days were 98%, 99%, and 
98% (P = 0.30).
1277 Underwent randomization
1837 Patients were assessed for eligibility
560 Were excluded
396 Had viral load <400 copies/ml
68 Had viral load ≤5000 copies/ml and no other
immunologic or clinical failure
21 Were ineligible for other reasons
3 Had poor adherence
9 Were pregnant or breast-feeding
7 Had renal, hepatic, or other disease
2 Required incompatible drugs
75 Were excluded for other reasons
33 Died or started second-line therapy
or were too sick to participate
40 Did not give consent or return
2 Missed enrollment deadline
426 Were assigned to the NRTI group
418 Were assigned to the monotherapy group
with a 12-wk raltegravir induction
30 Died before wk 96
4 Withdrew or were lost to follow-up
before wk 96
392 Were alive and in follow-up at wk 96
392 Had known disease status
11 Had missing CD4+ data
13 Had missing viral-load data
5 Had missing genotype information
(with viral load >1000 copies/ml)
22 Died before wk 96
7 Withdrew or were lost to follow-up
before wk 96
389 Were alive and in follow-up at wk 96
389 Had known disease status
10 Had missing CD4+ data
9 Had missing viral-load data
14 Had missing genotype information
(with viral load >1000 copies/ml)
433 Were assigned to the raltegravir group
426 Were included in analysis 418 Were included in analysis433 Were included in analysis
30 Died before wk 96
7 Withdrew or were lost to follow-up
before wk 96
396 Were alive and in follow-up at wk 96
396 Had known disease status
6 Had missing CD4+ data
5 Had missing viral-load data
6 Had missing genotype information
(with viral load >1000 copies/ml)
Figure 1. Enrollment and Outcomes.
At week 96, data for patients with missing values for the CD4+ count, viral load, or genotype were imputed for the analysis of the prima-
ry end point, according to the prespecified statistical analysis plan.
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efficacy End Points
Good HIV disease control (the primary end point) 
was achieved in 60% of the patients in the NRTI 
group (imputed mean based on multiple imputa-
tions from 25 simulations, 255 patients), 64% in 
the raltegravir group (imputed mean, 277 pa-
tients), and 55% in the monotherapy group (im-
puted mean, 232 patients). Patients receiving 
raltegravir, as compared with those receiving 
NRTIs, had a nonsignificant increase in the pri-
mary end point of 4.2 percentage points (95% 
confidence interval [CI], −2.4 to 10.7; P = 0.21; 
superiority not shown). Patients receiving prote-
ase-inhibitor monotherapy, as compared with 
those receiving NRTIs, had a nonsignificant de-
crease in the primary end point of −4.4 percent-
age points (95% CI, −11.2 to 2.4; noninferiority 
not shown, since the lower boundary exceeded 
the prespecified margin of 10 percentage points) 
(Table 2). The results did not differ significantly 
when observed data without imputation were 
used in the analysis (Table S5 in the Supplemen-
tary Appendix).
Similar proportions of patients (≥90%) in the 
three study groups were alive at week 96 with no 
new WHO grade 4 events (P = 0.73 for the com-
parison among the three groups) (Table 2, and 
Table S11 and Fig. S1 in the Supplementary Ap-
pendix). At 96 weeks, CD4+ counts were higher 
than 250 cells per cubic millimeter in 251 of 381 
patients (66%) in the NRTI group, 280 of 390 pa-
tients (72%) in the raltegravir group, and 243 of 
379 patients (64%) in the monotherapy group 
(P = 0.08 for the comparison between the NRTI 
group and the raltegravir group). The mean in-
crease in the CD4+ count at week 96 tended to be 
greater in the raltegravir group than in the NRTI 
group (P = 0.05) (Table 2, and Fig. S2 in the Supple-
mentary Appendix). Fewer patients in the mono-
therapy group than in the other two groups met 
the criterion for good disease control with re-
spect to viral load (P<0.001 for the comparison 
among the three groups). Sensitivity analyses 
showed similar results (Tables S5 and S7 in the 
Supplementary Appendix).
A viral load of less than 400 copies per milliliter 
at week 96 was reported in 86% of patients in the 
NRTI group as compared with 86% in the raltegra-
vir group (absolute risk difference, −0.1 percentage 
points; 95% CI, −5.0 to 4.8; P = 0.97) and 61% in 
the monotherapy group (absolute risk difference, 
−24.7 percentage points; 95% CI, −30.7 to −18.7; 
P<0.001) (Table 2 and Fig. 2A). There was no sig-
nificant difference between the NRTI group and 
the raltegravir group at any viral-load threshold 
that was evaluated (P>0.30 for all comparisons), 
whereas the proportion of patients with viral-
load suppression was significantly lower in the 
monotherapy group than in the NRTI group at 
all viral-load thresholds (P<0.01 for all compari-
sons), differences that were progressively larger 
at lower thresholds (Table 2 and Fig. 2A, and 
Table S6 in the Supplementary Appendix). No 
important heterogeneity was identified among 
groups (Tables S4 and S6 in the Supplementary 
Appendix).
Resistance Mutations
Intermediate- or high-level resistance to lopina-
vir was present at week 96 in 2% of patients in 
the NRTI group, 1% of those in the raltegravir 
group, and 18% of those in the monotherapy 
group (P<0.001 for the comparison among the 
three groups) (Table 2 and Fig. 2B). Among the 
genotype samples obtained from 194 patients, 
the major protease-inhibitor resistance mutations 
that were seen most frequently were 82A in 47 pa-
tients (24%), 46I in 43 patients (22%), and 76V in 
22 patients (11%). In the NRTI group, 4% of pa-
tients had intermediate- or high-level resistance 
to one or more NRTIs (with the exclusion of la-
mivudine and emtricitabine) taken during the 
trial; mutations included 70R in 10 patients, 67N 
in 9 patients, and 65R in 1 patient; mutations in 
TAM2 and TAM1 were found in 36 and 14 pa-
tients, respectively. In the raltegravir group, 3% 
of patients had intermediate- or high-level resis-
tance mutations to raltegravir (2 patients with 
143R, 3 patients with 155H, and 1 patient with 
140S+148H). In the monotherapy group, 4% of 
patients had intermediate-level resistance muta-
tions and no patients had high-level resistance 
mutations to darunavir.
Adverse Events
There were 312 serious adverse events (of which 
82 were fatal), 414 grade 3 or 4 adverse events (of 
which 61 were classified by the expert review 
committee as possibly, probably, or definitely re-
lated to a study drug), and 3 serious non-AIDS 
events, with no significant between-group differ-
ences (P>0.18 for all comparisons) (Table 3, and 
Tables S10 and S12 and Fig. S4 and S5 in the 
Supplementary Appendix). A total of 48 patients 
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(4%) had their drug regimen modified because of 
an adverse event (P = 0.28 for the comparison 
among the three groups); the most common rea-
sons reported were hematologic events in 4 pa-
tients in the NRTI group, rash or hypersensitiv-
ity reactions in 9 patients and hepatic events in 
6 patients in the raltegravir group, and hepatic 
events in 6 patients in the monotherapy group. At 
week 96, reductions in the estimated glomerular 
filtration rate were greater in the NRTI group 
(P = 0.02 as compared with the raltegravir group 
and P = 0.06 as compared with the monotherapy 
group), but there was no evidence of significant 
between-group differences in the proportion of 
patients with a rate of less than 60 ml per minute 
per 1.73 m2 (P = 0.22 for the comparison among 
the three groups) or the magnitude of the in-
crease in the hemoglobin level (P = 0.13 for the 
comparison among the three groups) (Table 3, and 
Fig. S6 and S7 in the Supplementary Appendix).
Discussion
In a randomized, controlled trial of second-line 
therapy in low-income countries in sub-Saharan 
Africa, we found that the WHO-recommended 
regimen of a boosted protease inhibitor (in this 
case, lopinavir) combined with two NRTIs was 
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
NRTI 
Group
(N = 426)
Raltegravir  
Group
(N = 433)
Monotherapy 
Group
(N = 418)
All Patients
(N = 1277)
Female sex — no. (%) 264 (62) 263 (61) 215 (51) 742 (58)
Age — yr
Median (IQR) 37 (31–43) 37 (30–43) 38 (32–44) 37 (31–44)
Range 12–73 12–75 12–71 12–75
Median weight (IQR) — kg 56.0 (48.9–63.7) 55.8 (48.8–64.0) 56.5 (50.0–64.8) 56.0 (49.2–64.0)
Median body-mass index (IQR)† 20 (18–23) 21 (18–23) 21 (18–23) 21 (18–23)
Disease status
WHO stage — no. (%)‡
Patients with available data 244 (57) 264 (61) 258 (62) 766 (60)
2  51 (12)  49 (11)  52 (12) 152 (12)
3 108 (25) 117 (27) 109 (26) 334 (26)
4  85 (20)  98 (23)  97 (23) 280 (22)
CD4+ count
Median (IQR) — cells/mm3 72 (29–143) 70 (27–142) 70 (33–149) 71 (30–146)
<100 cells/mm3 — no. (%) 262 (62) 267 (62) 258 (62) 787 (62)
Highest CD4+ count during first-line therapy
Patients with available data — no. (%) 330 (77) 351 (81) 338 (81) 1019 (80)
Median (IQR) — cells/mm3 257 (150–383) 233 (141–392) 236 (139–363) 243 (142–375)
Viral load
Median (IQR) — copies/ml 67,515
(23,065–175,800)
74,500
(25,004–205,000)
70,874
(21,584–210,000)
69,782
(23,183–194,690)
≥100,000 copies/ml — no. (%) 168 (39) 181 (42) 181 (43) 530 (42)
Previous antiretroviral therapy
Median duration (IQR) — yr 4.0 (2.8–5.4) 4.0 (2.9–5.5) 3.9 (2.6–5.4) 4.0 (2.8–5.4)
Drug — no. (%)
Zidovudine 292 (69) 283 (65) 287 (69) 862 (68)
Stavudine 266 (62) 266 (61) 245 (59) 777 (61)
Tenofovir  52 (12)  71 (16)  60 (14) 183 (14)
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Table 1. (Continued.)
Characteristic
NRTI  
Group
(N = 426)
Raltegravir  
Group
(N = 433)
Monotherapy 
Group
(N = 418)
All Patients
(N = 1277)
Treatment-failure criteria fulfilled — no. (%)
WHO stage 4 62 (15)  65 (15)  69 (17)  196 (15)
CD4+ count
Latest count <100/mm3 262 (62) 267 (62) 258 (62)  787 (62)
Latest count below count preceding initiation of 
first-line therapy
165 (39) 154 (36) 155 (37)  474 (37)
Latest count <200/mm3 with at least one previ-
ous count >400/mm3
47 (11)  49 (11)  40 (10)  136 (11)
Latest viral load >5000 copies/ml 402 (94) 403 (93) 388 (93) 1193 (93)
Laboratory values§
Hemoglobin — g/dl 11.9±2.2 11.9±2.2 12.0±2.1 11.9±2.2
Creatinine — mg/dl 0.74±0.28 0.76±0.37 0.78±0.37 0.76±0.34
Estimated glomerular filtration rate
Mean — ml/min/1.73 m2 114.7±37.6 114.8±39.1 112.5±38.0 114.0±38.2
<60 ml/min/1.73 m2 — no. (%) 17 (4) 18 (4) 25 (6)  60 (5)
* Plus–minus values are means ±SD. There were no significant differences among the groups except for sex (P = 0.003). To convert the values 
for creatinine to micromoles per liter, multiply by 88.4. IQR denotes interquartile range, and WHO World Health Organization.
† The body-mass index (the weight in kilograms divided by the square of the height in meters) was calculated for 1243 of the 1277 patients  
(97%).
‡ WHO stage was based on 2006 WHO case definitions.11
§ Values for hemoglobin, creatinine, and the estimated glomerular filtration rate were available for 1268 patients (99%), 1247 patients (98%), 
and 1238 patients (97%), respectively.
effective and had an acceptable safety profile, 
with a 90% rate of survival free of WHO stage 4 
events and an 86% rate of virologic suppression 
(<400 copies per milliliter) at 96 weeks. Although 
outcomes are often better in clinical trials than 
in clinical practice, our entry criteria were broad-
ly generalizable, and we followed the widely used 
approach of clinical and CD4+ monitoring, with-
out viral-load testing (apart from targeted testing 
to confirm treatment failure before changing 
therapy). At all study centers, we followed standard 
practice with respect to adherence counseling, 
which is a low-technology intervention that can 
be replicated in resource-limited settings. The 
good outcomes in the NRTI group in this trial are 
also consistent with the results of previous cohort 
studies in several resource-limited settings.19 Al-
though CD4+ counts increased, indicating im-
munologic recovery, only 66% of patients in the 
NRTI group had a CD4+ count of more than 250 
cells per cubic millimeter by 96 weeks, which 
probably reflects the low baseline CD4+ counts 
in patients at the time of the switch to second-
line therapy.20 However, even with persistently 
low CD4+ counts, patients receiving antiretrovi-
ral therapy would be expected to have reduced 
rates of HIV-related complications.21
Raltegravir was not superior to NRTIs when 
used in combination with a protease inhibitor in 
second-line therapy — an unexpected finding, 
given the predicted benefit associated with add-
ing a second new drug class without overlap 
with first-line treatment regimens. We considered 
it important to show that the raltegravir combi-
nation was superior, given the substantial addi-
tional cost of this agent, as compared with the 
cost of NRTIs, which is a major disadvantage for 
national treatment programs with finite resources. 
Nevertheless, the raltegravir combination was non-
inferior to the NRTI combination for all primary 
and secondary end points, findings that are con-
sistent with the results of a trial of lopinavir and 
raltegravir, as compared with lopinavir and NRTIs, 
as first-line therapy in high-income countries 
(with presumably full NRTI activity)22 and a 
trial of second-line therapy in high- and middle- 
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income countries with mainly genotyping-guided 
selection of NRTIs and viral-load monitoring.23 
We also found that the raltegravir combination 
had a safety profile similar to that of the NRTI 
combination and may therefore be an alternative 
second-line regimen in resource-rich settings where 
individualized therapy is feasible. The trend toward 
a modest advantage of raltegravir with respect to 
the increase in the CD4+ count, without differ-
ences in viral-load suppression, may reflect inde-
pendent effects of raltegravir on T-cell activation 
or survival,24,25 but there was no associated clinical 
benefit at week 96. Follow-up to week 144 will as-
sess longer-term outcomes and cost-effectiveness, 
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data that are essential for evaluating a new regi-
men before large-scale implementation.
We did not establish the noninferiority of 
protease-inhibitor monotherapy to combination 
therapy with NRTIs with respect to the primary 
end point, and monotherapy resulted in inferior 
viral-load suppression, which was associated with 
increased protease-inhibitor resistance. On the ba-
sis of these findings, the data and safety monitor-
ing committee recommended the discontinuation 
of the monotherapy group, and all patients in 
that group were switched to combination therapy. 
Several previous, noncomparative studies and one 
small, randomized study have suggested that pro-
tease-inhibitor monotherapy may be promising 
for second-line therapy in resource-limited set-
tings.26-28 The other small 48-week comparative 
trial in Thailand showed that protease-inhibitor 
monotherapy was inferior to protease-inhibitor 
therapy plus NRTIs on the basis of lower rates 
of viral-load suppression to a level under 50 copies 
per milliliter (with only a trend toward lower 
rates of suppression to a level under 400 copies 
per milliliter and little protease-inhibitor resis-
tance).29
Since outcomes with protease-inhibitor mono-
therapy are better when treatment is initiated 
after viral-load suppression,6,30,31 we used an induc-
tion approach with raltegravir. A longer induction 
period or a strategy including regular viral-load 
monitoring with immediate NRTI reintensification 
after viral-load rebound might have produced 
better outcomes, but such a regimen would be 
challenging to implement and would diminish 
the potential practical and cost advantages of 
protease-inhibitor monotherapy in resource-
limited settings. Although protease-inhibitor 
monotherapy may be a reasonable management 
strategy for individualized therapy, our findings 
indicate that it is not appropriate as a standard-
ized regimen in the public health approach. 
Nevertheless, the similar clinical and CD4+ 
outcomes in the NRTI and monotherapy groups 
provide reassurance that even when a regimen 
does not fully suppress the viral load, it can still 
provide benefits.
The comparison of the NRTI group with the 
monotherapy group allowed us to assess the 
contribution of NRTIs to second-line regimens 
in a population with first-line treatment failure 
and extensive NRTI cross-resistance, with NRTIs 
selected on the basis of simple algorithms with-
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out genotypic testing. In this setting, which is 
typical of most sub-Saharan African antiretroviral 
programs, the finding of substantial residual 
NRTI activity was remarkable. This may partly 
derive from the first use of tenofovir as a second-
line therapy in many patients, although a sub-
stantial proportion of patients had tenofovir re-
sistance at baseline. Results may also reflect 
residual antiviral-drug activity despite resistance 
or maintenance of viral populations with reduced 
replicative capacity (especially with the use of 
lamivudine, with the maintenance of the M184V 
mutation).32,33 Our findings can probably be gen-
eralized to settings in which viral-load monitor-
ing is used to detect first-line treatment failure 
earlier with less cross-resistance or settings in 
which resistance testing is available to guide the 
selection of NRTIs. In such settings, viral-load 
suppression in patients receiving combination 
therapy with an NRTI and a protease inhibitor 
might improve slightly, but this would decrease 
the likelihood of finding that a raltegravir combi-
nation is superior or that protease-inhibitor mono-
therapy is noninferior to an NRTI combination.
Similar rates of adverse events in the NRTI 
group as compared with the other groups and 
the low incidence of specific NRTI-attributable 
toxic effects (e.g., renal failure or severe anemia) 
are reassuring, especially given the challenges of 
routine laboratory safety monitoring in these set-
tings. When we began this study, the risk–benefit 
ratio of retaining NRTIs in second-line therapy 
was unclear, but our findings of substantial ef-
ficacy and minimal additional toxicity strongly 
support their use.
In conclusion, we found that boosted protease-
inhibitor therapy plus two NRTIs, administered 
without testing of genotypic resistance or regu-
lar viral-load monitoring and with limited labo-
ratory safety monitoring, had activity that was 
not surpassed by alternative regimens considered 
to be feasible in this setting.
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